Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bintrafusp Alfa with Chemotherapy for TKI-Resistant EGFR-Mutant NSCLC
NCT04971187Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2021
- Primary completion
- Feb 2022
- Modality
- Immune Checkpoint Inhibitors, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bintrafusp alfa in non-small cell lung cancer (NSCLC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Best Objective Response Rate at 6 months and Progression Free Survival at 18 weeks. Started Jun 2021; status: terminated.
02
Drugs
bintrafusp alfa
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04971187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04971187.